Financial Performance - The company's operating revenue for Q1 2023 was ¥119,423,435.11, a decrease of 0.85% compared to ¥120,451,245.21 in the same period last year[4] - Net profit attributable to shareholders was ¥4,024,418.08, down 69.15% from ¥13,044,337.80 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥115,039.00, a significant decline of 99.09% compared to ¥12,583,964.03 in the previous year[4] - The basic earnings per share decreased by 72.73% to ¥0.03 from ¥0.11 in the same period last year[4] - Net profit for Q1 2023 was CNY 3,651,134.29, down 71.5% from CNY 12,776,354.19 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was -¥57,394,913.52, worsening by 56.99% from -¥36,560,040.95 in the same period last year[4] - The net cash flow from operating activities decreased by 56.99% to -57,394,913.52 RMB due to reduced cash received from sales and increased cash paid for purchases[14] - The company reported a net cash outflow from operating activities of CNY -57,394,913.52, compared to CNY -36,560,040.95 in Q1 2022[21] - The net cash flow from investing activities increased by 125.81% to -148,163,433.78 RMB primarily due to cash spent on fixed asset construction for fundraising projects[14] - The net cash flow from financing activities decreased by 93.93% to 6,850,178.56 RMB, attributed to reduced minority shareholder investments and increased loan repayments[14] - The net cash increase for the period was -198,689,429.96 CNY, reflecting a challenging cash flow situation[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,076,908,041.96, an increase of 56.07% from ¥1,330,717,680.91 at the end of the previous year[5] - Total current assets decreased from 1,213,731,540.24 RMB to 1,063,291,961.48 RMB, with cash and cash equivalents dropping significantly[17] - The total liabilities increased to CNY 1,092,116,167.07, compared to CNY 1,087,176,743.47 in the previous year[20] - Short-term borrowings decreased from 321,630,876.40 RMB to 200,000,000.00 RMB, indicating a reduction in debt levels[17] - Long-term borrowings increased from 158,120,000.00 RMB to 288,497,770.11 RMB, suggesting a shift towards long-term financing[17] Shareholder Information - Shareholders' equity attributable to the parent company was ¥932,094,662.82, up 13.66% from ¥820,097,355.16 at the end of the previous year[5] - The number of common shareholders at the end of the reporting period was 16,351, with the largest shareholder holding 31.72% of the shares[14] - The total equity attributable to shareholders of the parent company was CNY 932,094,662.82, slightly up from CNY 928,070,078.38 in Q1 2022[20] Operational Costs and Expenses - Total operating costs increased to CNY 120,171,920.93, up 10.57% from CNY 108,873,562.70 in the previous year[19] - R&D expenses rose to CNY 10,545,515.62, an increase of 18.6% compared to CNY 8,891,743.44 in the same period last year[20] - The company reported an increase in financial expenses to CNY 2,868,072.48, compared to CNY 3,134,227.30 in Q1 2022[20] Other Financial Metrics - The weighted average return on equity fell to 0.43%, down 1.17% from 1.60% in the previous year[4] - Cash and cash equivalents decreased by 36.45% to ¥278,607,213.55 from ¥438,417,938.21 at the beginning of the year, primarily due to cash outflows for fixed asset purchases[9] - The company reported a significant increase in contract liabilities by 278.32%, reaching ¥2,104,208.06, compared to ¥556,201.33 at the beginning of the year[9] - The company reported a significant increase in accounts receivable from 172,850,260.34 RMB to 192,483,506.34 RMB, indicating potential cash flow issues[16] Audit and Reporting - The company did not conduct an audit for the first quarter report[23] - The cash flow from operating activities was not detailed in the provided data, indicating a potential area for further analysis[22]
共同药业(300966) - 2023 Q1 - 季度财报